3:58
ZUMA-1: a pivotal trial of CAR T-cells in NHL
Yi Lin
4:35
The use of anticoagulants in cancer-associated venous thromboembolism
Alejandro Lazo-Langner
6:30
GHSD HD18 study: reducing chemotherapy toxicity in advanced stage Hodgkin lymphoma
Peter Borchmann
4:38
Different is better: the fight against leukemia
Michaela Kotrová
7:25
Towards a world without blood disorders
Tony Green
3:42
Trial results of venetoclax plus CHOP therapy with rituximab or obinutuzumab in non-Hodgkin lymphoma
Andrew Zelenetz
2:52
Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL
Andrew Zelenetz
4:28
Erythromer, a nanoscale bio-synthetic artificial red cell
Allan Doctor
6:16
CPX-351 liposome injection vs standard cytarabine and daunorubicin for older high-risk AML patients
Jeffrey Lancet
6:32
Targeted factor VIII delivery in hemophilia with inhibitors
Caroline Hansen
6:57
MRD negative complete remissions following anti-CD22 CAR in relapsed/refractory ALL
Terry J. Fry
5:04
Novel therapies and unique delivery methods to improve treatment for bleeding crises, leukemia
Armand Keating
6:27
Adeno-associated virus mediated gene transfer for hemophilia B
Katherine A. High
5:29
Unmet clinical need: a low-cost, easy-to-use, portable platform for assessment of hemostasis
Evi Stavrou
6:02
EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response
François-Xavier Mahon
5:15
Clinical challenges in chronic myeloid leukemia
Mhairi Copland
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals